Dr. Reddy's Scouts for Partner to Enter Japanese Market (Japan)
This article was originally published in PharmAsia News
Dr Reddy's Laboratories is looking for a partner to help it enter the Japanese market. The second largest pharmaceutical market in the world, Japan represents 11 percent of global sales. Currently, only a small percentage of those are generics but as healthcare costs skyrocket that may be changing. In 2006, generic drug sales climbed 5.1 percent even though the market as a whole fell slightly. Dr. Reddy's is the latest Indian company to target the expanding Japanese generics market. Ranbaxy Laboratories teamed up with Nippon Chemiphar in 2005, and just last week Lupin said it would acquire Kyowa Pharmaceuticals. Cadila Healthcare also took control of Nippon Universal Pharmaceuticals earlier in 2007. (Click here for more
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.